ZMYND8 deletion boosts CD8+ T-cell effector function and synergizes with checkpoint blockade in mouse tumor models
ZMYND8 functions as an epigenetic brake on IL-2 receptor expression that drives CD8+ T-cell exhaustion; its deletion improves control of chronic infection and melanoma and enhances checkpoint or IL-2 therapy in mice. The findings derive from CRISPR screening and conditional knockout models published in Nature. Clinical translation will depend on selective inhibitors and confirmation in human T-cell systems.
The Nature study demonstrated that ZMYND8 binds p300 to repress Il2ra transcription after prolonged antigen exposure. In chronic LCMV and B16 melanoma models, conditional Zmynd8 knockout increased polyfunctional CD8+ T cells, reduced TOX and PD-1 expression, and extended survival compared with wild-type controls. Absolute increases reached 2.3-fold in IFN-γ+ TNF+ cells at day 21 post-infection.
Combination of Zmynd8 deletion with anti-PD-1 or high-dose IL-2 produced additive effects, raising complete regression rates from 20% to 55% in established tumors. These data align with prior observations that IL-2 signaling opposes exhaustion programs identified in 2019 Cell reports on progenitor exhausted T cells.
The work positions ZMYND8 as a druggable node downstream of signal 1 that decouples overstimulation from cytokine unresponsiveness, offering a potential orthogonal target to current checkpoint inhibitors.
Next steps require conditional humanized models and safety profiling of ZMYND8 inhibitors to test whether selective blockade preserves antiviral memory while reversing tumor-induced exhaustion.
Chi lab: First-in-human ZMYND8-targeted agent will reach IND filing by Q4 2027 with preclinical efficacy data showing >30% increase in tumor-infiltrating functional CD8+ T cells versus PD-1 monotherapy.
Sources (2)
- [1]Primary Source(https://www.nature.com/articles/s41586-026-11059-5)
- [2]Supporting Source(https://www.cell.com/cell/fulltext/S0092-8674(19)30334-4)